Pfizer said the vaccine, which is given to pregnant people to protect infants from birth, was safe, well-tolerated and had an efficacy of nearly 70% against severe respiratory illness from RSV in the first six months of life.
First RSV Vaccine On The Horizon—Pfizer Touts Strong Trial Results As Children’s Hospitals Count Soaring Cases
